Jennifer Dorrian

Statistics

Publications

Citations

416

H-Index

Active since

2012

Affiliations

Vertex Pharmaceuticals (United States)(Current)

Janssen (Belgium)

Janssen (United States)

Goethe University Frankfurt

University of Cincinnati Medical Center

Jennifer Dorrian is an author at Vertex Pharmaceuticals (United States) specializing in molecular virology, virology, and antiviral resistance mutations.

Publications per year

2012–2014

Publications

Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials

James C. Sullivan, Sandra De Meyer, Doug J. Bartels et al. · Clinical Infectious Diseases · 2013 · 165 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment

Doug J. Bartels, James C. Sullivan, Eileen Z. Zhang et al. · Journal of Virology · 2012 · 144 citations · Full text

Life Sciences, Infectious Diseases, Pharmacology +17

Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials

Tara L. Kieffer, Sandra De Meyer, Doug J. Bartels et al. · PLoS ONE · 2012 · 87 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17

Genotypic and Phenotypic Analyses of Hepatitis C Virus Variants Observed in Clinical Studies of VX-222, a Nonnucleoside NS5B Polymerase Inhibitor

Min Jiang, Eileen Z. Zhang, Andrzej Ardzinski et al. · Antimicrobial Agents and Chemotherapy · 2014 · 20 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17

1–4 of 4